Needham Raises Globus Medical to Buy with $112 Target; TD Cowen Sees Nevro, International Growth
Needham upgraded Globus Medical to Buy with a $112 price target after preliminary Q4 revenue. Needham forecasts expanding EBITDA margins—with a 20% estimate for Nevro—and expects EPS guidance to rise by high-single to low-double digits; TD Cowen set a $110 target and identified growth opportunities in Nevro and international markets.
1. Rating Upgrades and Price Targets
On January 30 Needham upgraded Globus Medical to a Buy rating and set a $112 price target, reflecting confidence after the company’s preliminary fourth-quarter revenue announcement. Earlier on January 26, TD Cowen initiated coverage with a Buy rating and a $110 target, citing potential for longer-term outperformance.
2. Margin and EPS Outlook
Needham highlighted expanding EBITDA margins, projecting a 20% margin for the Nevro segment, and expects these improvements to boost EPS guidance by a high-single to low-double digit percentage for fiscal 2026.
3. Growth Opportunities
TD Cowen identified key growth opportunities in the Nevro business segment, international market expansion, and enabling technologies, suggesting these areas could contribute to future organic revenue growth beyond current guidance.